Ensign Peak Advisors
KURA icon

Ensign Peak Advisors’s Kura Oncology KURA Stock Holding History

Ensign Peak Advisors’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-71,742
Closed -$1.03M – 1737
2023
Q4 		$1.03M Sell
71,742
-44,786
-38% -$440K ﹤0.01% 1354
2023
Q3 		$1.06M Hold
116,528
– – ﹤0.01% 1150
2023
Q2 		$1.23M Hold
116,528
– – ﹤0.01% 1102
2023
Q1 		$1.43M Hold
116,528
– – ﹤0.01% 980
2022
Q4 		$1.45M Buy
116,528
+11,776
+11% +$171K ﹤0.01% 938
2022
Q3 		$1.43M Buy
104,752
+29,426
+39% +$454K ﹤0.01% 908
2022
Q2 		$1.38M Buy
75,326
+69,446
+1,181% +$999K ﹤0.01% 963
2022
Q1 		$95K Hold
5,880
– – ﹤0.01% 2041
2021
Q4 		$82K Buy
+5,880
New +$95.3K ﹤0.01% 2097
2021
Q2 		– Sell
-35,339
Closed -$999K – 1845
2021
Q1 		$999K Hold
35,339
– – ﹤0.01% 1427
2020
Q4 		$1.15M Sell
35,339
-7,150
-17% -$251K ﹤0.01% 1342
2020
Q3 		$1.3M Buy
+42,489
New +$938K ﹤0.01% 1187
2020
Q2 		– Sell
-6,647
Closed -$66K – 1686
2020
Q1 		$66K Sell
6,647
-6,647
-50% -$76.1K ﹤0.01% 1594
2019
Q4 		$183K Buy
+13,294
New +$197K ﹤0.01% 1623

Other funds holding KURA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Ensign Peak Advisors's KURA Position: Q1 2024 in Review

Ensign Peak Advisors sold out of Kura Oncology (KURA) in Q1 2024, closing a stake of 71,742 shares — an estimated $1.03M sold.

Ensign Peak Advisors first reported a position in KURA in Q4 2019 and held it in 14 quarters. The position peaked at $1.45M in Q4 2022. 165 funds tracked by Wall St. Rank hold KURA as of Q1 2024.

  • Ensign Peak Advisors reported no remaining Kura Oncology position as of Q1 2024 after selling out during the quarter.
  • Ensign Peak Advisors sold 71,742 Kura Oncology shares in Q1 2024, an estimated $1.03M.
  • Ensign Peak Advisors first reported a position in Kura Oncology in Q4 2019 and held it in 14 quarters.
  • Ensign Peak Advisors's Kura Oncology position peaked at $1.45M in Q4 2022.
  • 165 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2024.

Based on Ensign Peak Advisors's 13F filing for Q1 2024, filed 14 May 2024.